Special Focus Review
Allergen immunotherapy for allergic respiratory diseases
Volume 8, Issue 10
Purchase or Subscribe
Pages 1499 - 1512http://dx.doi.org/10.4161/hv.21629
: adjuvant, allergen vaccine, immunopotentiator, sublingual immunotherapy, vector system
Authors: Antonio Cappella and Stephen R. Durham View affiliations
Allergen specific immunotherapy involves the repeated administration of allergen products in order to induce clinical and immunologic tolerance to the offending allergen. Immunotherapy is the only etiology-based treatment that has the potential for disease modification, as reflected by longterm remission following its discontinuation and possibly prevention of disease progression and onset of new allergic sensitizations. Whereas subcutaneous immunotherapy is of proven value in allergic rhinitis and asthma there is a risk of untoward side effects including rarely anaphylaxis. Recently the sublingual route has emerged as an effective and safer alternative. Whereas the efficacy of SLIT in seasonal allergy is now well-documented in adults and children, the available data for perennial allergies and asthma is less reliable and particularly lacking in children. This review evaluates the efficacy, safety and longterm benefits of SCIT and SLIT and highlights new findings regarding mechanisms, potential biomarkers and recent novel approaches for allergen immunotherapy.
Received: June 4, 2012; Accepted: July 26, 2012; Published Online: October 1, 2012
Full Text - Ahead of Print Available - Log in!